Efficacy and influencing factors of 3-N-Butylphthalide-trazodone combination in managing post-ischemic stroke depression

Table 4 Determinants of patients' curative effects by univariate analysis, n (%)

Indicators	Ineffective group (n = 21)	Effective group (n = 101)	χ2	P value
Age (years)			1.107	0.293
< 60	9 (42.86)	56 (55.45)
≥ 60	12 (57.14)	45 (44.55)
Male	12 (57.14)	63 (62.38)	0.201	0.654
Body mass index (kg/m2)			0.164	0.685
< 23	11 (52.38)	48 (47.52)
≥ 23	10 (47.62)	53 (52.48)
Stroke course (day)			1.055	0.304
< 20	7 (33.33)	46 (45.54)
≥ 20	14 (66.67)	55 (54.46)
Infarction site			0.332	0.847
Cortical and subcortical	10 (47.62)	53 (52.48)
Brainstem	6 (28.57)	23 (22.77)
Cerebellum	5 (23.81)	25 (24.75)
Hypertension	7 (33.33)	28 (27.72)	0.268	0.605
Diabetes	10 (47.62)	32 (31.68)	1.956	0.162
Hyperlipidaemia	8 (38.10)	18 (17.82)	4.261	0.039
NIHSS (points)			1.418	0.234
< 16	6 (28.57)	43 (42.57)
≥ 16	15 (71.43)	58 (57.43)
Barthel Index (points)			0.391	0.532
< 48	13 (61.90)	55 (54.46)
≥ 48	8 (38.10)	46 (45.54)
HAMD17 (points)			3.103	0.078
< 16	7 (33.33)	55 (54.46)
≥ 16	14 (66.67)	46 (45.54)
5-HT (ng/mL)			4.989	0.026
< 60	13 (61.90)	36 (35.64)
≥ 60	8 (38.10)	65 (64.36)
DA (ng/mL)			7.112	0.008
< 122	15 (71.43)	40 (39.60)
≥ 122	6 (28.57)	61 (60.40)
NE (ng/mL)			1.706	0.192
< 20	12 (57.14)	42 (41.58)
≥ 20	9 (42.86)	59 (58.42)
Medication regimen			4.405	0.036
3-N-Butylphthalide + Trazodonee	7 (33.33)	59 (58.42)
Trazodone	14 (66.67)	42 (41.58)

NIHSS: National Institutes of Health Stroke Scale; HAMD17: 17-item Hamilton Depression Rating Scale; 5-HT: 5-hydroxytryptamine; DA: Dopamine; NE: Norepinephrine.